|Bid||17.40 x 1800|
|Ask||17.47 x 2900|
|Day's range||17.06 - 17.55|
|52-week range||12.43 - 20.00|
|Beta (5Y monthly)||1.11|
|PE ratio (TTM)||21.53|
|Forward dividend & yield||0.85 (4.86%)|
|Ex-dividend date||29 Sep 2020|
|1y target est||22.61|
Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.
Merck (MRK) is stepping up to help Johnson & Johnson (JNJ) produce its COVID-19 vaccine, which was authorized last weekend.
Children's National Hospital and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program, which will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.